Exagen Announces Board Resignation and Committee Restructuring

Exagen ( (XGN) ) has provided an announcement.

On April 17, 2026, Exagen Inc. announced that director Ana Hooker resigned from the Board and all its committees, including her role as chair of the Nominating and Corporate Governance Committee and member of the Audit Committee, effective the same day, with no disagreement cited over company operations or policies. Following her departure, the Board reduced its size from eight to seven members and restructured the composition of the Audit, Compensation, and Nominating and Corporate Governance Committees, shifting responsibilities among remaining directors and maintaining designated committee chairs and a financial expert on the Audit Committee.

The most recent analyst rating on (XGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.

Spark’s Take on XGN Stock

According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.

Overall score is held down primarily by weak financial performance driven by continued operating losses and negative free cash flow. Technicals also remain unfavorable with the stock below key moving averages and negative MACD. Offsetting these, a positive corporate update showing record revenue and improved cash supports the outlook, but not enough to outweigh current profitability and cash-generation risks.

To see Spark’s full report on XGN stock, click here.

More about Exagen

Exagen Inc. operates in the healthcare sector as a diagnostic company, focusing on laboratory testing and related services. The company’s governance is overseen by a Board of Directors that includes specialized committees for audit, compensation, and nominating and corporate governance responsibilities.

Average Trading Volume: 341,275

Technical Sentiment Signal: Sell

Current Market Cap: $69.99M

Learn more about XGN stock on TipRanks’ Stock Analysis page.